证券日报网讯上海莱士（002252）9月8日在互动平台回答投资者提问时表示，公司非常重视全体股东的 合理投资回报，制定分红政策时，既会考量股东合理回报，也兼顾公司发展规划、财务状况等因素。当 前公司正处于业务拓展重要阶段，研发投入、产能扩充等方面资金需求较高。后续公司将持续优化经 营，在平衡公司发展与股东回报的基础上，合理规划分红政策。 ...

华银电力：股东拟减持不超过1%公司股份 9月5日晚，华银电力（600744）发布公告称，公司股东湖南能源集团有限公司（简称"湖南能源"）拟通 过集中竞价方式，减持公司股份合计不超过2031.12万股，不超过公司总股本的1%。 资料显示，华银电力成立于1993年3月，主营业务是火力发电业务，同时经营水电、风电、太阳能业务 以及电力销售业务。 所属行业：公用事业–电力–火电 安凯客车：8月客车销量773辆 9月5日晚，安凯客车（000868）发布公告称，公司8月客车产量为1012辆，同比增长68.06%；销量为 773辆，同比增长46.95%。其中，大型客车产量同比增长214.00%，销量同比增长164.26%。 资料显示，安凯客车成立于1997年7月，主营业务是客车整车及汽车零部件的研发、制造、销售和服务 于一体并坚持自主研发。 所属行业：汽车–商用车–商用载客车 联环药业：法莫替丁注射液获药品注册证书 9月5日晚，联环药业（600513）发布公告称，公司近日收到国家药品监督管理局核准签发的法莫替丁注 射液《药品注册证书》。该药品为化学药品3类，视同通过仿制药质量和疗效一致性评价。 资料显示，联环药业成立于20 ...

上海莱士：公司部分董事及全体高级管理人员计划6个月内增持公司股份不低于600万元 责任编辑：栎树 博威合金：A公司即将发布的首款AI手机的高端机型将全面使用公司的VC散热材料 国芯科技：新一代汽车电子BLDC电机驱动控制高性能芯片新产品内部测试成功 均胜电子：与智元机器人等头部客户合作，其中定制化主控板已实现批量供货 福立旺：机器人减速器等金属零部件已经开始出货交付 北京利尔：与商汤科技、曦望科技签署战略合作协议，探索AI算力合作等 先导智能：已成功打通全固态电池量产的全线工艺环节 铜冠铜箔：已开发出适用固态电池和半固态电池的铜箔产品 恒瑞医药：获得HRS-4729注射液临床试验批准通知书 宁波建工：下属子公司合计中标11.17亿元施工项目 中微公司：发布六款半导体设备新产品 建设银行：建信金租拟向建信航运航空增资30亿元 宇通客车：8月销量4260辆 同比增长16.78% 【增持】 【重要事项】 中国船舶：换股吸收合并中国重工，9月5日中国重工A股股票将终止上市 【业绩】 ...

| | | 9月4日重要公告精选 | | --- | --- | --- | | 类型 | 公司 | 主要内容 | | 热点 | 中环海陆 | 终止筹划公司控制权变更事项 股票复牌 | | 项目投资 | 石大胜华 | 拟设立子公司投资2500万元建设5.3 万吨/年氯化钙项目 | | 合同中标 | 东南网架 | 中标约16.86亿元浦沿街道五村联合统筹开发项目 | | 股权收购 | 罗曼股份 | 拟以1.96亿元收购武桐高新的39.2308%的股权 | | 回购 | 火炬电子 | 完成回购,已实际回购4999.07万元公司股份 | | 经营数据 | 江铃汽车 | 1-8月累计销量22.65万辆 同比增长5.67% | | | 温氏股份 | 8月肉鸡销售收入29.56亿元、生猪销售收入48.25亿元 | | 增减持 | 上海菜士 | 部分董事及全体高级管理人员拟增持不低于600万元公司股份 | | | 拱东医疗 | 实际控制人施慧勇拟大宗交易合计减持不超过440.99万股 | | | 济民健康 | 双鸽集团拟减持不超3%股份 | | 其他 | 中环海陆 | 终止筹划公司控制权变更事项 股票复牌 | | | 北京 ...

每经记者｜林姿辰 每经编辑｜张益铭 点评：本事件进一步丰富了公司及子公司的产品线，有助于提升公司及子公司产品的市场竞争力。但该 市场已有众多参与者，竞争激烈，公司需在营销、渠道拓展等方面发力，以实现市场份额的有效提升。 9月3日，先声药业与安帝康生物合作开发的玛氘诺沙韦颗粒上市申请获受理，拟用于2至11岁儿童无并 发症的甲型和乙型流感的治疗。这是中国首个成功完成III期临床并申报上市的针对儿童患者的抗流感病 毒创新药。 点评：首个国产儿童版抗流感新药若顺利获批，将为先声药业带来新的业务增长点，提升其在抗流感药 物市场的竞争力。同时，也体现了安帝康生物在创新药研发方面的实力，有助于提升其在资本市场的估 值。 NO.2 华神科技拟重新挂牌转让西藏康域51%股权 9月4日，华神科技发布公告，称公司拟重新挂牌转让控股子公司西藏康域药业有限公司51%股权，挂牌 价格为4250万元。公司已在西南联合产权交易所公示挂牌信息，但由于第二轮挂牌公告期满仍未征集到 符合条件的意向受让方，公司决定重新挂牌。 点评：前两轮挂牌未能征集到符合条件的意向受让方，可能意味着市场对此次股权出售的估值预期与公 司存在差异，或潜在买家对康域药业 ...

Group 1 - Guoxin Technology successfully tested a new generation of automotive electronic BLDC motor drive control high-performance chip "CBC2100B," which is based on 130nm BCD process and aims to address the MCU chip shortage in China's automotive industry, especially in new energy vehicles [1] - The chip is applicable in automotive electronic fields such as water pumps, oil pumps, and air conditioning fans, as well as in industrial control for BLDC motor drives and electrified equipment [1] Group 2 - Hangzhou High-tech experienced a change in control with the resignation of multiple key executives, including the chairman, vice chairman, and general manager, which may lead to a temporary reduction in the board's member count below the minimum required [2] - The resigning executives will continue to perform their duties until new appointments are made to ensure the company's normal operations [2] Group 3 - Zhonghuan Hailu decided to terminate the planning of a change in control due to disagreements with the trading party regarding future development arrangements [4] - The stock and convertible bonds of the company will resume trading on September 5, 2025 [4] Group 4 - ST Tianmao plans to voluntarily withdraw its A-shares from trading on the Shenzhen Stock Exchange and apply for transfer to the National SME Share Transfer System after the termination of listing [5] - The decision has been approved by the company's first temporary shareholders' meeting in 2025 [5] Group 5 - Beijing Lier signed a strategic cooperation agreement with SenseTime and Xiwang to explore AI computing power collaboration and the development of industrial manufacturing and decision-making AI vertical models [6] - Hunan Baiyin adjusted its share repurchase price ceiling from 5 yuan to 7 yuan per share due to the stock price exceeding the original limit [6] Group 6 - Dongnan Network won the bid for the "Pujiang Street Five Villages Joint Development Project" with a bid amount of 1.686 billion yuan, accounting for 15% of the company's audited revenue for 2024 [8] - Wens Foodstuff reported sales of 3.2457 million pigs in August 2025, generating revenue of 4.825 billion yuan, with a year-on-year price change of 37.88% [8] - Jiangling Motors sold 30,003 vehicles in August 2025, representing a year-on-year increase of 8.92% [8] Group 7 - Hubei Yihua completed the construction of a 200,000 tons/year caustic soda energy-saving renovation project, which has been put into production [9] - Satellite Chemical announced routine maintenance for its polyethylene and ethylene oxide/ethylene glycol facilities, expected to last 45 days [9] Group 8 - Shida Shenghua plans to establish a subsidiary for a 53,000 tons/year calcium chloride project with an investment of 25 million yuan, aimed at enhancing its resource advantages in the new energy materials sector [11] - Roman Co. intends to acquire a 39.2308% stake in Wutong Technology for 196.154 million yuan, which will make Wutong a subsidiary of Roman [11] Group 9 - Shanghai Laishi's executives plan to increase their shareholdings in the company with a total investment of no less than 6 million yuan [13]

证券日报网讯 9月4日晚间，上海莱士发布公告称，公司副董事长兼总经理JunXu（徐俊）先生、副总经 理沈积慧先生、副总经理陆晖先生、副总经理兼董事会秘书刘峥先生、副总经理宋正敏女士、财务负责 人陈乐奇先生、副总经理黄勤兵先生计划自本公告披露之日起6个月内增持公司股份，拟增持金额合计 不低于人民币600万元，增持所需的资金来源为自筹资金。本次增持计划不设置增持股份价格区间，增 持人将基于对公司股票价值的合理判断，择机实施本次增持计划。 （文章来源：证券日报） ...

(本文来自第一财经) 诺力股份：实控人及其一致行动人等拟合计减持不超3.11%股份； 拱东医疗：实控人及一致行动人拟合计减持不超3%股份； 济民健康：实控人之一致行动人拟减持不超3%股份； 国光连锁：实控人拟合计减持公司不超2.99%股份； 嘉和美康：弘云久康拟减持公司不超1%股份； 博隆技术：监事会主席拟减持公司不超0.75%股份； 长飞光纤：长江通信拟减持公司不超0.15%股份； 国瓷材料：股东王红拟减持公司股份不超300万股。 上海莱士：部分高管拟合计不低于600万元增持公司股份； ...

Core Viewpoint - Haier Group is rapidly expanding in the health industry, having acquired three A-share companies: Shanghai Laishi, Haier Bio, and Yinkang Life, creating a diverse portfolio in blood products, medical devices, and healthcare services [1][3]. Financial Performance - Shanghai Laishi reported a revenue of approximately 3.952 billion yuan, a year-on-year decrease of 7.06%, and a net profit of about 1.03 billion yuan, down 17% [3]. - Haier Bio's revenue was around 1.196 billion yuan, a decline of 2.27%, with a net profit of 143 million yuan, down 39.09% [4]. - Yinkang Life was the only company to show net profit growth, achieving a revenue of 843 million yuan, up 2.4%, and a net profit of 61.83 million yuan, up 12.82% [4]. Goodwill Concerns - All three companies have significant goodwill on their balance sheets, with Shanghai Laishi's goodwill reaching 8.308 billion yuan, an increase from 5.073 billion yuan the previous year [6]. - Yinkang Life's goodwill increased to 1.012 billion yuan from 693 million yuan, while Haier Bio's goodwill stood at 759 million yuan [7]. - The high goodwill poses a risk of impairment, which could adversely affect net profits if the acquired companies underperform [7]. Industry Challenges - Shanghai Laishi faces intense competition in the blood products sector, with pricing pressures due to market consolidation [9]. - Haier Bio is experiencing a downturn in the low-temperature storage equipment market and is diversifying into new sectors to mitigate this decline [9]. - Yinkang Life is focused on building a comprehensive healthcare ecosystem, emphasizing original technology and clinical value [10]. Strategic Direction - Haier's strategy involves a combination of acquisitions and organic growth to establish a full-chain layout in the health sector, leveraging its strengths in manufacturing and supply chain management [10][11]. - The company aims to balance capital expansion with stable operations, emphasizing meticulous management and long-term strategies to address short-term challenges [11].

公告显示，前述增持人系出于对公司拓浆脱浆战略发展规划的坚定信心及长期投资价值的充分认可，结 合当前资本市场形势，为进一步增强投资者信心，拟进行增持。 北京商报讯（记者 丁宁）9月4日晚间，上海莱士（002252）发布公告称，公司副董事长兼总经理 Jun Xu （徐俊） 、副总经理沈积慧、副总经理陆晖、副总经理兼董事会秘书刘峥、副总经理宋正敏、财务 负责人陈乐奇、副总经理黄勤兵计划自公告披露之日起6个月内增持公司股份，拟增持金额合计不低于 600万元，增持所需的资金来源为自筹资金。 ...